WealthPlan Investment Management LLC Purchases 12,634 Shares of Pfizer Inc. (NYSE:PFE)

WealthPlan Investment Management LLC increased its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 536.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,989 shares of the biopharmaceutical company’s stock after acquiring an additional 12,634 shares during the period. WealthPlan Investment Management LLC’s holdings in Pfizer were worth $497,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. RB Capital Management LLC raised its stake in shares of Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after acquiring an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. increased its position in shares of Pfizer by 1.1% during the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after buying an additional 400 shares during the period. United Bank increased its position in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after buying an additional 290 shares during the period. Ergoteles LLC increased its position in shares of Pfizer by 136.3% during the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after buying an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp increased its position in shares of Pfizer by 6.4% during the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after buying an additional 79,887 shares during the period. Institutional investors own 68.05% of the company’s stock.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb purchased 3,000 shares of the stock in a transaction dated Friday, December 15th. The shares were bought at an average price of $26.47 per share, with a total value of $79,410.00. Following the completion of the transaction, the director now directly owns 9,000 shares in the company, valued at approximately $238,230. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.05% of the company’s stock.

Pfizer Stock Down 0.0 %

PFE opened at $27.56 on Monday. The firm has a market capitalization of $155.62 billion, a P/E ratio of 76.56, a PEG ratio of 1.22 and a beta of 0.62. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.38 and a quick ratio of 2.05. Pfizer Inc. has a fifty-two week low of $25.76 and a fifty-two week high of $44.20. The company’s 50-day moving average is $28.19 and its 200 day moving average is $31.36.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.61%. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.14 earnings per share. Research analysts expect that Pfizer Inc. will post 2.23 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Shareholders of record on Friday, January 26th will be given a $0.42 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.41. The ex-dividend date of this dividend is Thursday, January 25th. This represents a $1.68 annualized dividend and a yield of 6.10%. Pfizer’s payout ratio is currently 466.67%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PFE. BMO Capital Markets decreased their price objective on shares of Pfizer from $44.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, October 16th. Jefferies Financial Group upgraded shares of Pfizer from a “hold” rating to a “buy” rating and increased their price objective for the stock from $38.00 to $39.00 in a research report on Monday, October 16th. Wells Fargo & Company decreased their price objective on shares of Pfizer from $39.00 to $35.00 and set an “equal weight” rating for the company in a research report on Monday, October 16th. Citigroup reduced their price target on shares of Pfizer from $42.00 to $35.00 and set a “neutral” rating for the company in a report on Monday, October 16th. Finally, Truist Financial reduced their price target on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, December 14th. Eleven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $36.93.

Get Our Latest Analysis on PFE

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.